Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dofetilide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 known ✓ | Q12809 | 9/20 | 1.00 |
| ▸ | CACNA1F | O60840 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 1.00 |
| ▸ | AGTR1 | P30556 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | CACNA1D | Q01668 | 1/20 | 1.00 |
| ▸ | CACNA1S | Q13698 | 1/20 | 1.00 |
| ▸ | CACNA1C | Q13936 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dofetilide SCHEMBL6102734 | 1.00 | KCNH2 (1.00) | KCNH2CACNA1FCHRM2ACHEAGTR1 | |
| Dofetilide SCHEMBL8362214 | 0.99 | KCNH2 (0.97) | KCNH2CACNA1FCHRM2ACHEAGTR1 | |
| SCHEMBL9628071 | 0.94 | KCNH2 (0.88) | KCNH2CACNA1FCHRM2ACHEAGTR1 | |
| SCHEMBL9628293 | 0.94 | KCNH2 (0.88) | KCNH2CACNA1FCHRM2ACHEAGTR1 | |
| SCHEMBL26239229 | 0.94 | KCNH2 (0.88) | KCNH2CACNA1FCHRM2ACHEAGTR1 | |
| SCHEMBL24600680 | 0.94 | KCNH2 (0.88) | KCNH2CACNA1FCHRM2ACHEAGTR1 | |
| Hydrochloric Acid SCHEMBL9629110 | 0.92 | KCNH2 (0.84) | KCNH2CACNA1FCHRM2ACHEAGTR1 | |
| SCHEMBL18678464 | 0.92 | KCNH2 (0.84) | KCNH2CACNA1FCHRM2ACHEAGTR1 | |
| Hydrochloric Acid SCHEMBL9629115 | 0.92 | KCNH2 (0.84) | KCNH2CACNA1FCHRM2ACHEAGTR1 | |
| SCHEMBL9628048 | 0.90 | KCNH2 (0.80) | KCNH2CACNA1FCHRM2ACHEAGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 8222 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102339-A1 | ARTIFICIAL INTELLIGENCE-BASED METHOD AND SYSTEM FOR RAPID DRUG SCREENING USING INTRACELLULAR ELECTRICAL RECORDINGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-15 | — | — | WO | claimed |
| US-12617809-B2 | Cardioprotective lipid and method of use | SIGNPATH PHARMA, INC. (US) | 2026-05-05 | — | — | US | claimed |
| US-12576074-B2 | Kits and methods for induction of cardioversion in subjects with atrial arrhythmias | INCARDA THERAPEUTICS, INC. (US) | 2026-03-17 | — | — | US | claimed |
| EP-4705765-A2 | BUCCAL CELL DIAGNOSIS OF RISK IN FAMILIAL ARRHYTHMIA SYNDROMES | Beth Israel Deaconess Medical Center, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| US-12569183-B2 | Method of administering sotalol IV/switch | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2026-03-10 | — | — | US | claimed |
| US-12521357-B2 | Intravenous dofetilide to convert atrial fibrillation/flutter | HYLORIS DEVELOPMENTS SA (BE) | 2026-01-13 | — | — | US | claimed |
| US-20250387389-A1 | METHODS OF TREATING DISEASE WITH LEVOKETOCONAZOLE | XERIS PHARMACEUTICALS, INC. (US) | 2025-12-25 | — | — | US | claimed |
| US-12474326-B2 | Treatment methods having reduced drug-related toxicity and methods of identifying the likelihood of patient harm from prescribed medications | TABULA RASA HEALTHCARE, INC. (US) | 2025-11-18 | — | — | US | claimed |
| US-20250350689-A1 | INTRAVENOUS DOFETILIDE AND USES THEREOF | HYLORIS DEV SA (BE) | 2025-11-13 | — | — | US | claimed |
| US-20250345297-A1 | ANTI-ARRHYTHMIC COMPOSITIONS AND METHODS | AltaThera Pharmaceuticals LLC (US) | 2025-11-13 | — | — | US | claimed |
| EP-0988009-A1 | DEVICE AND METHOD FOR TREATMENT OF DYSMENORRHEA | UMD, Inc. (US) | 2000-03-29 | — | — | EP | claimed |
| EP-0965341-A2 | Combination of dofetilide and a calcium channel blocker | Pfizer Products Inc. (US) | 1999-12-22 | — | — | EP | claimed |
| WO-1999064050-A1 | NOVEL POTASSIUM CHANNEL DRUGS AND THEIR USES | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | claimed |
| WO-1999021829-A1 | DOFETILIDE POLYMORPHS | PFIZER LIMITED (GB) | 1999-05-06 | — | — | WO | claimed |
| EP-0898964-A1 | Method for treating heart failure | PFIZER INC. (US) | 1999-03-03 | — | — | EP | claimed |
| WO-1998056323-A1 | DEVICE AND METHOD FOR TREATMENT OF DYSMENORRHEA | UMD, INC. (US) | 1998-12-17 | — | — | WO | claimed |
| EP-0752859-A1 | PHARMACEUTICAL COMPOSITION CONTAINING A CLASS III ANTIARRHYTHMIC AGENT AND A CLASS IV ANTIARRHYTHMIC AGENT | SMITHKLINE BEECHAM LABORATOIRES PHARMACEUTIQUES (FR) | 1997-01-15 | — | — | EP | claimed |
| WO-1995026726-A1 | PHARMACEUTICAL COMPOSITION CONTAINING A CLASS III ANTIARRHYTHMIC AGENT AND A CLASS IV ANTIARRHYTHMIC AGENT | SMITHKLINE BEECHAM LABORATOIRES PHARMACEUTIQUES (FR) | 1995-10-12 | — | — | WO | claimed |
| EP-0245997-B1 | N-SUBSTITUTED P-AMINOETHYLSULPHON ANILIDES AS ANTIARRHYTHMIC AGENTS, AND INTERMEDIATES THEREFOR | Pfizer Limited (GB) | 1992-04-15 | — | — | EP | claimed |
| EP-0245997-A2 | N-substituted p-aminoethylsulphon anilides as antiarrhythmic agents, and intermediates therefor | Pfizer Limited (GB) | 1987-11-19 | — | — | EP | claimed |